Table III.
Summary of clinical characteristics, management strategies and outcomes of all pooled patients.
| Characteristics (n=81) | Value (percentage among available data) |
|---|---|
| Demographics | |
| Median age, Range (N=68) | 39, 18–82 Yrs. |
| Gender (N=81) | Male: 44 (54.3%) |
| Most common presenting symptoms (N=65) | No. (%) |
| Headache | 13 (20.0%) |
| Decreased visual acuity | 11 (16.9%) |
| Nausea and vomiting | 9 (13.8%) |
| Motor deficit | 7 (10.8%) |
| Diplopia | 7 (10.8%) |
| Ataxia | 6 (9.2%) |
| Memory impairment | 4 (6.2%) |
| Vertical gaze palsy | 3 (4.6%) |
| Decreased level of consciousness | 3 (4.6%) |
| Dizziness | 2 (3.1%) |
| Hydrocephalus (N=50) | No. (%) |
| Ventriculoperitoneal shunt | 20 (40.0%) |
| Endoscopic third ventriculostomy | 12 (24.0%) |
| Not shunted | 18 (36.0%) |
| KPS | Median, Range |
| Pre-operative (N=21) | 60, 30–100 |
| Post-operative (N=1) | 60 |
| Tumor size (N=27) | Median, Range |
| Median | 3.8 cm |
| Range | 2–6 cm |
| Histopathological type/Grade (N=56) | No. (%) |
| Glioblastoma IV | 28 (50.0%) |
| Astrocytoma II | 11 (19.6%) |
| Unspecified grade astrocytoma | 5 (8.9%) |
| Anaplastic astrocytoma III | 4 (7.1%) |
| Ependymoma II | 3 (5.4%) |
| Gliosarcoma IV | 2 (3.6%) |
| Pilocytic astrocytoma I | 1 (1.8%) |
| Ganglioglioma I | 1 (1.8%) |
| Central neurocytoma I | 1 (1.8%) |
| Surgery (n=81) | No. (%) |
| Gross-total resection (≥98%) | 28 (34.6%) |
| Sub-total resection (80–97%) | 33 (40.7%) |
| Partial resection (<80%) | 7.4 (7.4%) |
| Biopsy | 14 (17.3%) |
| Surgical approach (N=61) | No. (%) |
| Supracerebellar infratentorial approach | 38 (62.3%) |
| Transcortical transventricular approach | 11 (18.0%) |
| Transcallosal interhemispheric approach | 8 (13.1%) |
| Occipital transtentorial approach | 2 (3.3%) |
| Supracerebeloso suboccipital approach | 1 (1.6%) |
| Transcortical/Subchoroidal approach | 1 (1.6%) |
| Adjuvant therapy (N=53) | No. (% among all cases) |
| Chemotherapy | 26 (32.1%) |
| Radiotherapy | 33 (40.7%) |
| Median dose (Range) | 5,770cGy (1,800–10,080) |
| Outcomes (Months) | Median (Range) |
| Progression free survival (N=44) | 11.3 (2–78) |
| Overall survival (N=46) | 12.0 (2–78) |
| Recurrence | 12 (14.8%) |
| Status (N=51) | No. (%) |
| Alive | 15 (29.4%) |
| Dead | 36 (70.6%) |